Caribou Biosciences, Inc. announced that its CB-011 cell therapy product candidate has received Fast Track designation for relapsed or refractory multiple myeloma from the FDA.
AI Assistant
CARIBOU BIOSCIENCES INC
2023
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.